세계의 종양학 기반 In-Vivo CRO 시장 보고서(2025년)

Oncology Based In-Vivo CRO Global Market Report 2025

US $ 4,490 ￦ 6,457,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,334,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,211,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

종양학 기반 In-Vivo CRO 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 22억 7,000만 달러로 성장하며 CAGR은 10.9%가 됩니다. 예측 기간의 성장은 새로운 시장 기회, 면역 종양학 치료로의 전환, 종양학 임상시험 증가, 정밀의료, 표적 치료로 인한 것으로 예측됩니다. 예측 기간의 주요 동향에는 재생 의료 및 세포 요법, 신속한 의약품 개발에 대한 수요, 디지털화 및 데이터 분석, 종양 미세 환경에 대한 관심, 생물학적 제제 및 면역 요법 증가가 포함됩니다.

향후 5년간의 성장률 10.9%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과는 PDX 마우스 모델(중국)과 마이크로이미징 스캐너(네덜란드)의 비용을 증가시키고, 암 치료제의 승인을 늦추고, 연구 개발비를 증가시킬 수 있기 때문에 미국의 임상시험에 과제를 가져올 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

암 이환율 증가는 암을 기반으로 한 생체내 의약품 개발 업무 수탁기관(CRO) 시장의 향후 성장을 가속할 것으로 예측됩니다. 암은 비정상적인 세포가 무질서하게 분열되어 주변 조직에 침입하여 혈액과 림프계를 통해 신체의 다른 부분으로 퍼질 수 있는 질환군에 의해 특징지어집니다. 효과적인 암 진단 및 치료에는 혁신적인 의약품 및 의료기기가 필요하며, 시장에 나가기 전까지는 다양한 전임상시험, 임상시험, 규제 과정을 거쳐야 합니다. 종양학 기반 In-vivo CRO는 인간 임상시험에 앞서 전임상 In-vivo 시험(동물, 식물, 전체 세포 등의 생체를 이용한 시험)에 관련된 단계의 전부 또는 일부를 실시하는 것을 포함한 연구 서비스를 제공하기 위해 스폰서로부터 계약을 맺은 기업입니다. 암 이환율이 계속 상승하는 가운데 혁신적인 치료나 치료법에 대한 수요도 증가하고 있으며, 종양학 기반 In-vivo CRO 시장 성장을 뒷받침하고 있습니다. 예를 들어 미국을 거점으로 하는 비영리단체인 미국암협회는 2022년 국내에서 확인된 암 관련 사망자 수는 약 60만 9,000명, 신규암 환자수는 190만 명으로 보고했습니다. 2024년에는 사망률의 약간의 상승을 반영하여 추정 62만명의 암 사망자가 있었습니다. 그 결과, 암의 유병률의 상승이 종양학 기반 In-vivo CRO 시장 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 종양학 기반 In-Vivo CRO : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 종양학 기반 In-Vivo CRO 시장 : 성장률 분석
• 세계의 종양학 기반 In-Vivo CRO 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 종양학 기반 In-Vivo CRO 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 종양학 기반 In-Vivo CRO : 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 종양학 기반 In-Vivo CRO 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 혈액암
• 고형암
• 기타 적응증
• 세계의 종양학 기반 In-Vivo CRO 시장 : 모델별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 동계 모델
• 이종 이식 모델
• 환자 유래 이종 이식 모델(PDX)
• 기타 모델
• 세계의 종양학 기반 In-Vivo CRO 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 재활센터
• 세계의 종양학 기반 In-Vivo CRO 시장 : 혈액암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 백혈병
• 림프종
• 골수종
• 세계의 종양학 기반 In-Vivo CRO 시장 : 고형암 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 유방암
• 폐암
• 대장암
• 전립선암
• 기타 고형 종양
• 세계의 종양학 기반 In-Vivo CRO 시장 : 기타 적응증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 신경모세포종
• 생식세포종
• 육종
• 기타 특정 적응증

제7장 지역별/국가별 분석

• 세계의 종양학 기반 In-Vivo CRO 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 종양학 기반 In-Vivo CRO 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 종양학 기반 In-Vivo CRO 시장 : 경쟁 구도
• 종양학 기반 In-Vivo CRO 시장 : 기업 프로파일
  • Crown Bioscience : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Charles River Laboratories International Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Taconic Biosciences Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • The Jackson Laboratory : 개요, 제품 및 서비스, 전략 및 재무 분석
  • ICON plc. : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• WuXi AppTec Inc.
• EurofIns Scientific SE
• Labcorp Drug Development
• Champion Oncology Inc.
• Xentech SAS
• Thermo Fisher Scientific Inc.
• MI Bioresearch Inc.
• ClIntec International Private Limited
• Worldwide ClInical Trials Inc.
• Pharm-Olam LLC
• ClInipace ClInical Research Private Limited
• Covance Inc.
• Evotec SE
• LivIng Tumor Laboratory
• Oncodesign SA

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 종양학 기반 In-Vivo CRO 시장(2029년) : 새로운 기회를 제공하는 국가
• 종양학 기반 In-Vivo CRO 시장(2029년) : 새로운 기회를 제공하는 부문
• 종양학 기반 In-Vivo CRO 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

An oncology-focused in-vivo contract research organization (CRO) is a company contracted by another entity to conduct various stages of preclinical in-vivo studies for oncology drugs or devices. This includes designing, overseeing, monitoring, and analyzing preclinical in-vivo research involving living organisms such as animals, plants, or cells.

The primary areas of focus for oncology-based in-vivo CROs encompass blood cancer, solid tumors, and other related indications. Blood cancers originate from tissues responsible for blood formation, such as immune cells and bone marrow, including leukemia, lymphoma, and multiple myeloma. These CROs provide in-vivo testing services utilizing models such as blood cancer-based xenografts and others to expedite drug development research, aiding sponsors of drugs and devices in gaining market approval. Various models, including syngeneic, xenograft, patient-derived xenograft (PDX), and others, are employed by oncology-based in-vivo CROs and applied within hospital and rehabilitation settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The oncology based in-vivo CRO software market research report is one of a series of new reports from The Business Research Company that provides oncology based in-vivo CRO software market statistics, including oncology based in-vivo CRO software industry global market size, regional shares, competitors with a oncology based in-vivo CRO software market share, detailed oncology based in-vivo CRO software market segments, market trends and opportunities, and any further data you may need to thrive in the oncology based in-vivo CRO software industry. This oncology based in-vivo CRO software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology based in-vivo cro market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing focus on oncology therapeutics, increasing incidence of cancer, shift towards personalized medicine, pharmaceutical industry growth, and demand for target-specific therapies.

The oncology based in-vivo cro market size is expected to see rapid growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to emerging market opportunities, a shift towards immuno-oncology therapies, a rise in oncology clinical trials, precision medicine, and targeted therapies. Major trends in the forecast period include regenerative medicine and cell therapies, demand for faster drug development, digitalization and data analytics, focus on tumor microenvironment, and rise in biologics and immunotherapies.

The forecast of 10.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose challenges for U.S. clinical trials by raising costs for PDX mouse models (China) and microimaging scanners (Netherlands), potentially delaying oncology drug approvals and increasing research and development (R&D) expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of cancer is projected to drive growth in the oncology-based in-vivo contract research organization (CRO) market in the future. Cancer is characterized by a group of diseases where abnormal cells divide uncontrollably, invade surrounding tissues, and can spread to other parts of the body via the blood and lymphatic systems. Effective cancer diagnosis and treatment necessitate innovative drugs and devices that undergo various preclinical trials, clinical trials, and regulatory processes before they can reach the market. An oncology in-vivo CRO is a company contracted by a sponsor to provide research services, including conducting all or part of the steps involved in preclinical in-vivo studies (testing on living organisms such as animals, plants, or whole cells) prior to human trials. As the prevalence of cancer continues to rise, the demand for innovative treatments and therapies is also increasing, thereby propelling the growth of the oncology-based in-vivo CRO market. For example, the American Cancer Society, a non-profit organization based in the U.S., reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases identified in the country in 2022. In 2024, an estimated 620,000 cancer deaths are anticipated, reflecting a slight increase in mortality rates. Consequently, the rising prevalence of cancer is driving growth in the oncology-based in-vivo CRO market.

The upsurge in healthcare spending is expected to drive the expansion of the oncology-based in-vitro CRO market. Healthcare expenditure, encompassing costs related to healthcare services, significantly influences the development and accessibility of in-vitro CRO services within the oncology sector. Notably, the Canadian Institute for Health Information reported a rise in healthcare expenditure to $331 billion in 2022, indicating an 0.8% increase from the previous year. This surge in spending accentuates the market's growth within the oncology-based in-vitro CRO domain.

Leading companies in the oncology-based in-vivo CRO market are increasingly focusing on personalized oncology models to establish a competitive edge. These personalized oncology models leverage patient-derived xenografts (PDXs) to develop customized treatment strategies, thereby improving the relevance and effectiveness of preclinical studies. For example, in 2022, Charles River Laboratories, a life sciences company based in the U.S., introduced its OncoMouse platform, which utilizes PDX technology for more precise tumor modeling. This platform offers high-throughput screening capabilities and real-time monitoring of tumor growth, facilitating quick evaluations of therapeutic responses. Furthermore, it includes integrated data analytics to refine treatment protocols according to individual patient profiles. These developments represent a significant shift toward more effective and patient-focused methods in cancer research.

Companies within this market segment are focusing on novel solutions such as CAR T-cell therapies to gain a competitive edge. For instance, Seattle Children's Hospital and Research Institute launched BrainChild Bio in May 2023, targeting CAR T-cell therapies for pediatric brain tumors such as diffuse intrinsic pontine gliomas (DIPG). This platform incorporates synthetic technologies to enhance CAR T-cell therapy for CNS malignancies, aiming to expand its applications to other challenging brain tumors such as glioblastoma and brain metastases. The pursuit of these innovative therapies signifies a strategic move to advance treatment options within the oncology-based in-vivo CRO market.

In March 2023, ClinChoice Medical Development, a US-based contract research organization (CRO) that provides research services to accelerate drug and device approvals, acquired Cromsource S.r.l. for an undisclosed amount. Through this acquisition, ClinChoice Medical Development expands its operational capabilities with additional delivery hubs to complement its existing network in Europe and the US. Data science technology offerings in several areas, including risk-based monitoring and decentralized clinical trials, are expanded through acquisition. Cromsource S.r.l. is an Italy-based contract research organization that provides full-research services to the pharmaceutical, biotechnology, and medical device industries.

Major companies operating in the oncology based in-vivo cro market include Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

North America was the largest region in the oncology based in-vivo CRO market in 2024. North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the oncology based in-vivo cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oncology-based in-vivo CRO market includes revenues earned by entities by providing preclinical research services such as in-vivo testing via models such as Orthotopic tumor models, tumor passaging, tissue culture models, and others for oncology drugs and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Based In-Vivo CRO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology based in-vivo cro market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology based in-vivo cro ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology based in-vivo cro market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Blood Cancer; Solid Tumors; Other Indications
• 2) By Model: Syngeneic Model; Xenograft; Patient Derived Xenograft (PDX); Other Models
• 3) By Application: Hospitals; Rehabilitation Centers
• Subsegments:
• 1) By Blood Cancer: Leukemia; Lymphoma; Myeloma
• 2) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Solid Tumors
• 3) By Other Indications: Neuroblastoma; Germ Cell Tumors; Sarcomas; Other Specific Indications
• Companies Mentioned: Crown Bioscience; Charles River Laboratories International Inc.; Taconic Biosciences Inc.; The Jackson Laboratory; ICON plc.; WuXi AppTec Inc.; Eurofins Scientific SE; Labcorp Drug Development; Champion Oncology Inc.; Xentech SAS; Thermo Fisher Scientific Inc.; MI Bioresearch Inc.; Clintec International Private Limited; Worldwide Clinical Trials Inc.; Pharm-Olam LLC; Clinipace Clinical Research Private Limited; Covance Inc.; Evotec SE; Living Tumor Laboratory; Oncodesign SA; Pharmaron Beijing Co. Ltd.; Syngene International Limited; GenScript Biotech Corporation; Shanghai Medicilon Inc.; Oncolys BioPharma Inc.; Pharmalegacy Laboratories; Oncotest GmbH; Oncovision; Biocytogen LLC; Innovent Biologics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Based In-Vivo CRO Market Characteristics

3. Oncology Based In-Vivo CRO Market Trends And Strategies

4. Oncology Based In-Vivo CRO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Oncology Based In-Vivo CRO Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncology Based In-Vivo CRO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncology Based In-Vivo CRO Market Growth Rate Analysis
• 5.4. Global Oncology Based In-Vivo CRO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncology Based In-Vivo CRO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncology Based In-Vivo CRO Total Addressable Market (TAM)

6. Oncology Based In-Vivo CRO Market Segmentation

• 6.1. Global Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Cancer
• Solid Tumors
• Other Indications
• 6.2. Global Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Syngeneic Model
• Xenograft
• Patient Derived Xenograft (PDX)
• Other Models
• 6.3. Global Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Rehabilitation Centers
• 6.4. Global Oncology Based In-Vivo CRO Market, Sub-Segmentation Of Blood Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Lymphoma
• Myeloma
• 6.5. Global Oncology Based In-Vivo CRO Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Solid Tumors
• 6.6. Global Oncology Based In-Vivo CRO Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neuroblastoma
• Germ Cell Tumors
• Sarcomas
• Other Specific Indications

7. Oncology Based In-Vivo CRO Market Regional And Country Analysis

• 7.1. Global Oncology Based In-Vivo CRO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncology Based In-Vivo CRO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Based In-Vivo CRO Market

• 8.1. Asia-Pacific Oncology Based In-Vivo CRO Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Based In-Vivo CRO Market

• 9.1. China Oncology Based In-Vivo CRO Market Overview
• 9.2. China Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Based In-Vivo CRO Market

• 10.1. India Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Based In-Vivo CRO Market

• 11.1. Japan Oncology Based In-Vivo CRO Market Overview
• 11.2. Japan Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Based In-Vivo CRO Market

• 12.1. Australia Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Based In-Vivo CRO Market

• 13.1. Indonesia Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Based In-Vivo CRO Market

• 14.1. South Korea Oncology Based In-Vivo CRO Market Overview
• 14.2. South Korea Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Based In-Vivo CRO Market

• 15.1. Western Europe Oncology Based In-Vivo CRO Market Overview
• 15.2. Western Europe Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Based In-Vivo CRO Market

• 16.1. UK Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Based In-Vivo CRO Market

• 17.1. Germany Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Based In-Vivo CRO Market

• 18.1. France Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Based In-Vivo CRO Market

• 19.1. Italy Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Based In-Vivo CRO Market

• 20.1. Spain Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Based In-Vivo CRO Market

• 21.1. Eastern Europe Oncology Based In-Vivo CRO Market Overview
• 21.2. Eastern Europe Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Based In-Vivo CRO Market

• 22.1. Russia Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Based In-Vivo CRO Market

• 23.1. North America Oncology Based In-Vivo CRO Market Overview
• 23.2. North America Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Based In-Vivo CRO Market

• 24.1. USA Oncology Based In-Vivo CRO Market Overview
• 24.2. USA Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Based In-Vivo CRO Market

• 25.1. Canada Oncology Based In-Vivo CRO Market Overview
• 25.2. Canada Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Based In-Vivo CRO Market

• 26.1. South America Oncology Based In-Vivo CRO Market Overview
• 26.2. South America Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Based In-Vivo CRO Market

• 27.1. Brazil Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Based In-Vivo CRO Market

• 28.1. Middle East Oncology Based In-Vivo CRO Market Overview
• 28.2. Middle East Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Based In-Vivo CRO Market

• 29.1. Africa Oncology Based In-Vivo CRO Market Overview
• 29.2. Africa Oncology Based In-Vivo CRO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncology Based In-Vivo CRO Market, Segmentation By Model, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncology Based In-Vivo CRO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Based In-Vivo CRO Market Competitive Landscape And Company Profiles

• 30.1. Oncology Based In-Vivo CRO Market Competitive Landscape
• 30.2. Oncology Based In-Vivo CRO Market Company Profiles
  • 30.2.1. Crown Bioscience Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Taconic Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. The Jackson Laboratory Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. ICON plc. Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Based In-Vivo CRO Market Other Major And Innovative Companies

• 31.1. WuXi AppTec Inc.
• 31.2. Eurofins Scientific SE
• 31.3. Labcorp Drug Development
• 31.4. Champion Oncology Inc.
• 31.5. Xentech SAS
• 31.6. Thermo Fisher Scientific Inc.
• 31.7. MI Bioresearch Inc.
• 31.8. Clintec International Private Limited
• 31.9. Worldwide Clinical Trials Inc.
• 31.10. Pharm-Olam LLC
• 31.11. Clinipace Clinical Research Private Limited
• 31.12. Covance Inc.
• 31.13. Evotec SE
• 31.14. Living Tumor Laboratory
• 31.15. Oncodesign SA

32. Global Oncology Based In-Vivo CRO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Based In-Vivo CRO Market

34. Recent Developments In The Oncology Based In-Vivo CRO Market

35. Oncology Based In-Vivo CRO Market High Potential Countries, Segments and Strategies

• 35.1 Oncology Based In-Vivo CRO Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncology Based In-Vivo CRO Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncology Based In-Vivo CRO Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료